Pivotal phase III study of T cell vaccine Tcelna in patients with relapsing-remitting multiple sclerosis.
Phase of Trial: Phase III
Latest Information Update: 08 Nov 2011
At a glance
- Drugs Imilecleucel-T (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Sponsors Opexa Therapeutics
- 08 Nov 2011 Opexa plans to initiate a phase IIb trial in patients with secondary progressive multiple sclerosis, while remaining committed to further advancing the product in relapsing-remitting multiple sclerosis at a later date.
- 06 Jan 2011 New trial record